Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

Blood

Volumn 113, Issue 19, 2009, Pages 4667-4676

  Kuhn, Deborah J ^a   Hunsucker, Sally A ^a   Chen, Qing ^b   Voorhees, Peter M ^b   Orlowski, Marian ^c   Orlowski, Robert Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DERIVATIVE; BORTEZOMIB; CASPASE; DEXAMETHASONE; IPSI 001; PEPTIDYL ALDEHYDE DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BORONIC ACID DERIVATIVE; DIPEPTIDE; IPSI-001; MESSENGER RNA; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; CELL DEATH; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN PURIFICATION; APOPTOSIS; BINDING COMPETITION; CELL CULTURE; CHROMOSOME 13; CHROMOSOME DELETION; CYTOLOGY; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; IMMUNOBLOTTING; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BINDING, COMPETITIVE; BORONIC ACIDS; CELLS, CULTURED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; DEXAMETHASONE; DIPEPTIDES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOBLOTTING; MULTIPLE MYELOMA; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UMBILICAL VEINS;

EID: 66549099025     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-171637     Document Type: Article

References (63)

1. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14:1649-1657.
2. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005;6:79-87.
3. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684. (Pubitemid 46237441)
4. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874. (Pubitemid 46655613)
5. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24:2105-2112. (Pubitemid 46622122)
6. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617. (Pubitemid 36741588)
7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498. (Pubitemid 41007864)
8. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557-3560. (Pubitemid 350159621)
9. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-3901. (Pubitemid 47477266)
10. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281-3290. (Pubitemid 350106321)
11. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8:407-419. (Pubitemid 41579835)
12. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer. 2006;95:961-965. (Pubitemid 44606819)
13. Unno M, Mizushima T, Morimoto Y, et al. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002;10:609-618. (Pubitemid 34518706)
14. Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol Today. 1992;13:173-179.
15. Orlowski M, Wilk S. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides. Biochem Biophys Res Commun. 1981;101:814-822. (Pubitemid 12205196)
16. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta. 2004;1695:225-233. (Pubitemid 39574976)
17. Noda C, Tanahashi N, Shimbara N, Hendil KB, Tanaka K. Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats. Biochem Biophys Res Commun. 2000;277:348-354. (Pubitemid 30807474)
18. Jiang H, Monaco JJ. Sequence and expression of mouse proteasome activator PA28 and the related autoantigen Ki. Immunogenetics. 1997;46:93-98. (Pubitemid 27234705)
19. Eleuteri AM, Angeletti M, Lupidi G, Tacconi R, Bini L, Fioretti E. Isolation and characterization of bovine thymus multicatalytic proteinase complex. Protein Expr Purif. 2000;18:160-168. (Pubitemid 30172221)
20. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999;17:739-779. (Pubitemid 29241139)
21. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature. 1993;365:264-267. (Pubitemid 23282087)
22. Früh K, Gossen M, Wang K, Bujard H, Peterson PA, Yang Y. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J. 1994;13:3236-3244. (Pubitemid 24226938)
23. Rivett AJ, Hearn AR. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr Protein Pept Sci. 2004;5:153-161.
24. Teoh CY, Davies KJ. Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: the 'PrOxI' hypothesis. Arch Biochem Biophys. 2004;423:88-96.
25. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, Kloetzel PM. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev. 2005;207:19-30. (Pubitemid 41415005)
26. Díaz-Hernández M, Hernandez F, Martin-Aparicio E, et al. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci. 2003;23:11653-11661. (Pubitemid 38021292)
27. Mishto M, Bellavista E, Santoro A, et al. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging. 2006;27:54-66. (Pubitemid 41627950)
28. Ethen CM, Hussong SA, Reilly C, Feng X, Olsen TW, Ferrington DA. Transformation of the proteasome with age-related macular degeneration. FEBS Lett. 2007;581:885-890. (Pubitemid 46282718)
29. Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis Colon Rectum. 2007;50:337-348; discussion 348-350.
30. Visekruna A, Joeris T, Seidel D, et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest. 2006;116:3195-3203. (Pubitemid 44878633)
31. Egerer T, Martinez-Gamboa L, Dankof A, et al. Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome. Arthritis Rheum. 2006;54:1501-1508.
32. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005;65:7896-7901. (Pubitemid 41297267)
33. Orlowski M, Cardozo C, Eleuteri AM, Kohanski R, Kam CM, Powers JC. Reactions of [14C]-3,4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complexes (proteasomes). Biochemistry. 1997;36:13946-13953.
34. Cardozo C, Michaud C, Orlowski M. Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues. Biochemistry. 1999;38:9768-9777. (Pubitemid 129515277)
35. Ovaa H. Active-site directed probes to report enzymatic action in the ubiquitin proteasome system. Nat Rev Cancer. 2007;7:613-620.
36. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276:13322-13330. (Pubitemid 37385264)
37. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther. 2003;307:861-869. (Pubitemid 37494202)
38. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258:479-517. (Pubitemid 41705391)
39. Lauricella M, Emanuele S, D'Anneo A, et al. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis. 2006;11:607-625.
40. Tsuruta F, Sunayama J, Mori Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J. 2004;23:1889-1899. (Pubitemid 38649651)
41. Engelberg D. Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol. 2004;14:271-282.
42. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83:731-801.
43. Huang Z, McGowan EB, Detwiler TC. Ester and amide derivatives of E64c as inhibitors of platelet calpains. J Med Chem. 1992;35:2048-2054.
44. Chen J, Wersinger C, Sidhu A. Chronic stimulation of D1 dopamine receptors in human SKN-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J Biol Chem. 2003;278:28089-28100. (Pubitemid 36900006)
45. Goldoni M, Vettori MV, Alinovi R, Caglieri A, Ceccatelli S, Mutti A. Models of neurotoxicity: extrapolation of benchmark doses in vitro. Risk Anal. 2003;23:505-514. (Pubitemid 36693483)
46. Cristòfol RM, Gasso S, Vilchez D, Pertusa M, Rodriguez-Farre E, Sanfeliu C. Neurotoxic effects of trimethyltin and triethyltin on human fetal neuron and astrocyte cultures: a comparative study with rat neuronal cultures and human cell lines. Toxicol Lett. 2004;152:35-46. (Pubitemid 39030785)
47. Sebastià J, Pertusa M, Vilchez D, et al. Carboxyl-terminal fragment of amyloid precursor protein and hydrogen peroxide induce neuronal cell death through different pathways. J Neural Transm. 2006;113:1837-1845. (Pubitemid 44749623)
48. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91:929-934. (Pubitemid 44023146)
49. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006;42:1612-1622. (Pubitemid 44118763)
50. Orlowski M. Selective activation of the 20 S proteasome (multicatalytic proteinase complex) by histone H3. Biochemistry. 2001;40:15318-15326. (Pubitemid 33151946)
51. Aki M, Shimbara N, Takashina M, et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem (Tokyo). 1994;115:257-269. (Pubitemid 2041850)
52. Leblond J, Hubert-Buron A, Bole-Feysot C, Ducrotte P, Dechelotte P, Coeffier M. Regulation of proteolysis by cytokines in the human intestinal epithelial cell line HCT-8: role of IFNgamma. Biochimie. 2006;88:759-765.
53. Khan S, van den Broek M, Schwarz K, de Giuli R, Diener PA, Groettrup M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol. 2001;167:6859-6868. (Pubitemid 33144178)
54. Singh S, Awasthi N, Egwuagu CE, Wagner BJ. Immunoproteasome expression in a nonimmune tissue, the ocular lens. Arch Biochem Biophys. 2002;405:147-153. (Pubitemid 35191726)
55. Hemeryck A, Geerts R, Monbaliu J, et al. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol. 2007;60:777-787. (Pubitemid 47389383)
56. Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A, Buee L. Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett. 2005;579:1-5. (Pubitemid 40023365)
57. Młynarczuk-Biały I, Roeckmann H, Kuckelkorn U, et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res. 2006;66:7598-7605. (Pubitemid 44289216)
58. Kisselev AF, Akopian TN, Castillo V, Goldberg AL. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell. 1999;4:395-402. (Pubitemid 29499792)
59. Salzmann U, Kral S, Braun B, et al. Mutational analysis of subunit i beta2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS Lett. 1999;454:11-15. (Pubitemid 29296916)
60. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, Kim K-B. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol. 2007;14:419-430. (Pubitemid 46617320)
61. Schmidtke G, Emch S, Groettrup M, Holzhutter HG. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome. J Biol Chem. 2000;275:22056-22063. (Pubitemid 30621783)
62. Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell. 2001;7:411-420. (Pubitemid 32206508)
63. Kisselev AF, Garcia-Calvo M, Overkleeft HS, et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem. 2003;278:35869-35877. (Pubitemid 37139904)